You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
再進一步!腦機接口公司Neuralink為首次人體試驗招募志願者
格隆匯 09-20 08:56

當地時間週二,馬斯克旗下的腦機接口公司Neuralink宣佈,已獲得一個獨立審查委員會的批准,將進行首次人體試驗,對癱瘓患者的大腦植入設備,開始招募臨牀實驗患者。

公吿顯示,此次試驗“旨在評估植入物(N1)和手術機器人(R1)的安全性,並評估腦機接口的初始功能,使癱瘓患者能夠用自己的思想控制外部設備。”

因此,那些因頸脊髓損傷或肌萎縮側索硬化症而癱瘓的人可能有資格參加此次試驗,但Neuralink沒有透露具體將有多少名參與者。

據Neuralink一些員工爆料,Neuralink早些時候曾希望獲得批准,可以在10名患者中植入該設備,但在美國食品藥品監督管理局(FDA)提出安全問題後,該公司正在與該機構就減少患者數量進行談判。目前尚不清楚美國食品藥品監督管理局最終批准了多少患者。

Neuralink透露,這項研究將使用機器人通過手術將腦機接口(BCI)植入物放置在大腦中控制移動意圖的區域,其最初目標是使人們能夠單獨使用自己的思想控制計算機光標或鍵盤。

此外,據介紹,這項人體試驗為期六年,參與者將首先參加一項為期18個月的研究,在那之後,他們將每週至少花兩個小時進行腦機接口方面的研究。

商業化還需要很長時間

回顧來看,今年5月,Neuralink表示,它的首次人體臨牀試驗獲得了FDA的批准。

此前,馬斯克曾表示,Neuralink的短期目標是幫助癱瘓者實現意念打字功能,未來還將可以實現讓癱瘓者行走、讓盲人看見,並最終實現“人機共生體”。

馬斯克還聲稱。他計劃有一天自己接受Neuralink的植入物。

另據麥肯錫此前預測,未來10到20年,全球腦機接口產業將產生700億美元-2000億美元經濟價值。儘管市場前景廣大,但行業目前仍處於發展早期階段。

有專家表示,即使腦機接口設備被證明對人類使用是安全的,Neuralink仍可能需要十多年的時間才能獲得商業使用許可。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account